THE ART and SCIENCE of Managing the New Melanoma Landscape

4th Annual Collaborative Conference









Focus

This conference will be comprised of multiple sessions led by national experts in melanoma. With the focus on multidisciplinary management and unraveling molecular mechanisms, the scientific agenda will be comprehensive and effective in addressing the educational needs of the target audience of clinicians who treat people with melanoma. It will also address the importance of multidisciplinary communications and management strategies for pre-clinical and clinical management along the disease continuum.

This unique medical oncology conference seamlessly combines the varied investigative focus of melanoma researchers with narrowing or closing unmet professional medical education needs of clinicians managing patients with melanoma. Case presentations by faculty experts will link cutting-edge clinical research with the significant scientific discoveries that have occurred over the past decade that have driven forward patient-centered care in melanoma. Faculty will present foundational evidence, emergent therapies, keys to selecting appropriate therapies, and offer practical approaches to incorporating the various biologic and genetic markers of import in melanoma into clinical practices.

Through lectures, case presentations and panel discussions, this course is designed to meet the continuing medical education needs of medical oncologists, dermatologists, surgical oncologists, dermatopathologists, and all other healthcare providers managing patients with Melanoma.

Educational Objectives

After attending the conference, participants should be able to:

- Utilize the latest criteria and clinical evidence for treatment options for melanoma
 patients with clinically localized disease and interpret the components of
 the updated AJCC staging system for melanoma (Knowledge, Competence,
 Performance);
- Utilize the latest criteria and clinical evidence for treatment options for melanoma
 patients with regional disease and interpret the components of the updated AJCC
 staging system for melanoma (Knowledge, Competence, Performance);
- Evaluate latest criteria and clinical evidence to sequence/combine therapies in melanoma patients with distant metastases (*Knowledge, Competence*);
- Appraise the most recent evidence on biomarkers and other patient selection criteria to choose treatments in patients with advanced/metastatic melanoma (Knowledge, Competence, Performance, Patient Outcomes);
- Identify potential toxicities of current therapies and strategies to improve patient outcomes (*Knowledge, Competence, Performance, Patient Outcomes*).

Educational Methods

Lecture/Didactic • Case Study • Panel Discussions
Audience Response System • Question/Answer Session

Target Audience

This conference should be of value to medical oncologists, surgical oncologists, dermatologists, nurse practitioners, physician assistants and oncology nurses.

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

Physicians

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Points

American Board of Internal Medicine

participation in the evaluation component, enables the participant to earn up to 10.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful completion of this CME activity, which includes

In order to receive MOC points, you must pass the post-test with a score of 70% or higher.

American Board of Surgery

This live activity is approved for AMA PRA Category 1 Credits™ and has met the American Board of Surgery (ABS) requirements. Successful completion of this CME activity, which includes participation in the self-assessment component, enables the participant to earn self-assessment credits toward Part 2 of the ABS MOC Program.

CME Certificates and Attendance Verification Certificates

Certificates awarding AMA PRA Category

1 Credit™ or certificates documenting
attendance will be distributed to participants
as they depart the conference. To obtain a
CME certificate, physicians must submit a
completed evaluation questionnaire and a
CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Physician Payments-Sunshine Act

MD Anderson complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

MD Anderson Planning Committee

Merrick I. Ross, MD

(Co-Chair)

Professor Surgical Oncology

Michael A. Davies, MD, PhD

(Co-Chair)

Associate Professor Deputy Chair Melanoma Medical Oncology

Patrick Hwu, MD

(Co-Chair)

Division Head Cancer Medicine Chair

Melanoma Medical Oncology

Allison Baring, CMP

Senior Conference Coordinator CME/Conference Management

CONFERENCE AGENDA

Friday, September 22, 2017

Noon	Registration and Box Lunch Pick Up	7:00 am	Registration and Continental Breakfast
1:00 pm	Welcome and Introduction Patrick Hwu, MD	Session 3	Metastatic Melanoma: Targeted Therapy, Immunotherapy, and Biomarkers to Personalized Care
Session 1	Melanoma Prevention, Screening, Diagnosis, and Staging	8:00 am	Immunotherapy Michael K. Wong, MD, PhD
1:15	Melanoma Diagnosis and Screening (including new phone apps and digital approaches to diagnose skin lesions) Ana M. Ciurea, MD	8:25	Targeted Therapy Ryan J. Sullivan, MD
1:35	The New AJCC Melanoma Staging System Jeffrey E. Gershenwald, MD	8:50	Use of Biomarkers to Guide Care Michael Tetzlaff, MD, PhD
1:55	Emerging Prognostic Markers in Melanoma Jeffrey E. Lee, MD	9:15	Optimal First-Line Therapy for Metastatic Melanoma Hussein Tawbi, MD, PhD
2:15	Surgical Management of Primary Melanoma Merrick I. Ross, MD	9:40	Multidisciplinary Panel
		10:40	Break
2:35	Multidisciplinary Panel	Session 4	The Art of Melanoma Management
3:35	Break		•
3:35		Session 4 10:55	The Art of Melanoma Management Understanding and Overcoming Resistance to Systemic Therapies Jennifer Wargo, MD
3:35	Break Management of Regional Disease: Current and Emerging		Understanding and Overcoming Resistance to Systemic Therapies
3:35 Session 2	Management of Regional Disease: Current and Emerging Strategies Surgery and Intralesional Therapy	10:55	Understanding and Overcoming Resistance to Systemic Therapies Jennifer Wargo, MD Managing Toxicities of Targeted and Immune Therapies
3:35 Session 2 3:45	Management of Regional Disease: Current and Emerging Strategies Surgery and Intralesional Therapy Robert H. I. Andtbacka, MD, CM Radiation	10:55	Understanding and Overcoming Resistance to Systemic Therapies Jennifer Wargo, MD Managing Toxicities of Targeted and Immune Therapies Adi Diab, MD CNS Metastases
3:35 Session 2 3:45 4:10	Management of Regional Disease: Current and Emerging Strategies Surgery and Intralesional Therapy Robert H. I. Andtbacka, MD, CM Radiation Ashleigh Guadagnolo, MD, MPH Adjuvant and Neoadjuvant Systemic Therapy	10:55 11:20 11:45	Understanding and Overcoming Resistance to Systemic Therapies Jennifer Wargo, MD Managing Toxicities of Targeted and Immune Therapies Adi Diab, MD CNS Metastases Isabella C. Glitza Oliva, MD, PhD Non-Cutaneous Melanomas (Mucosal and Uveal)

Saturday, September 23, 2017

MD Anderson Faculty

Rodabe N. Amaria, MD

Assistant Professor Melanoma Medical Oncology

Ana M. Ciurea, MD

Associate Professor Dermatology

Adi Diab, MD

Assistant Professor Melanoma Medical Oncology

Jeffrev E. Gershenwald, MD

Professor

Surgical Oncology

Isabella C. Glitza Oliva. MD. PhD Surgical Oncology

Assistant Professor Melanoma Medical Oncology Ashleigh Guadagnolo, MD, MPH

Associate Professor Radiation Oncology

Patrick Hwu, MD

Division Head Cancer Medicine

Melanoma Medical Oncology

Jeffrev E. Lee. MD

Chair

Surgical Oncology

Merrick I. Ross. MD

Professor

Guest Faculty

Kelly C. Nelson, MD

Panelists

Additional

Clinical Associate Professor Dermatology

Alexander Lazar, MD, PhD Professor Pathology

Robert H.I. Andtbacka, MD, CM

Associate Professor Surgical Oncology University of Utah School of Medicine Co-Director Melanoma Program & Melanoma Clinical Research Program Huntsman Cancer Institute Salt Lake City, Utah

Ryan J. Sullivan, MD Assistant Professor

Hussein Tawbi, MD, PhD

Melanoma Medical Oncology

Michael Tetzlaff, MD, PhD

Pathology Administration

Michael K. Wong, MD, PhD

Melanoma Medical Oncology

Associate Professor

Associate Professor

Jennifer Wargo, MD

Associate Professor

Surgical Oncology

Professor

Medicine Harvard Medical School Assistant Professor Hematology/Oncology Massachusetts General Hospital

Boston, Massachusetts

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Registration Information

On-site registration opens at Noon on Friday, September 22. Box lunches will be available. The Welcome and Introductions will begin at 1:00 pm and the conference will adjourn at 2:00 pm on Saturday, September 23. Advanced registration is encouraged as space and materials are limited.

The deadline for advanced registration is Monday, August 7, 2017.

There are three ways to register:

- 1. Online at www.mdanderson.org/conferences
- 2. Fax to: 713-794-1724
- 3. Mail to: CME/Conference Management Unit 1781

The University of Texas MD Anderson Cancer Center

P.O. Box 301407,

Houston, TX 77230-1407

We accept the following forms of payment:

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The conference registration fee includes tuition, final conference agenda, continental breakfasts, breaks, and lunch. Please refer to the registration form for specific information regarding fees.

Refund/Cancellation Policy

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before Monday, August 7, 2017. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, please contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866

Special Assistance

Contact the Department of CME/Conference Management at 713-792-2223 or tollfree at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations

- A block of rooms has been reserved for conference attendees at the Houston Marriott Medical Center located at 6580 Fannin Street, Houston, Texas.
- Early hotel reservation is suggested and the room block cutoff date is: Thursday, August 31, 2017.
- The hotel phone number is 1-800-228-9290.
- When you make reservations, be sure to mention the group name: **MD Anderson** Melanoma Meeting room block to be assured of receiving the special meeting rate of \$110 for a standard guest room. Please add 17% Texas state and local taxes.

Ground Transportation

(prices are subject to change and variable depending on location of conference)

- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).
- Taxicabs are available at an estimated cost for \$50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport.
- Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott Medical Center for \$27 one-way and \$54 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www.supershuttle.com.
- Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott Medical Center for \$24 one-way and \$48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www. supershuttle.com.

The University of Texas MD Anderson Cancer Center does not endorse the commercial products, equipment, or services presented by program supporters/ exhibitors.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

The Art and Science of Managing the

176700/30/117037/41

The Art and Science of Managing the New Melanoma Landscape-

4th Annual Collaborative Conference —

Last Name

CONFERENCE REGISTRATION -

September 22- 23, 2017

ement - Unit 1781 4th Annual Collaborative Conference

						Partition of other partitions of the partition of the par
Department (include unit no.)		Specialty				Ine University of lexas MID Anderson Cancer Center PO Box 301407, Houston, TX 77230-1407
Institution						or fax to 713-794-1724 Make check or money order payable to:
MD Anderson Employee ID No. (required	o. (required for all MDACC employees):	ployees):	Physician	□ Yes □ No	No	The University of Texas MD Anderson Cancer Center
Street						Registration Fees
City			State/Foreign	State/Foreign Country/Zip or Mail Code	Code	Physicians (MDs/DOs)
Daytime Phone (with area code)		Cell Phone (with area code)	Fax	Fax (with area code)		☐ Postmarked before August 7
E-mail Address (please print)	-					
Emergency Contact		Phone (with area code)	ea code)			
Credit Card Holder Name (First/Last'	st/Last)			Charge the following: ☐ VISA ☐ MC	ng: 1C	☐ Postmarked after August /
Credit Card Number				Expiration Date		
Security Code/CVV/CSV (Credit Card Holder Billing Address & ZIP Code	ess & ZIP Code				☐ Postmarked before August 7\$50 ☐ Postmarked after August 7\$75
MD Anderson Interdepartmental Trai	nental Transfer (IDT) No.: *	nsfer (IDT) No.: *Fund Group 90 will not be accepted	be accepted			So
Business Unit	Department	Fund Group* Fund	Fund		Fund Type	Staff/TraineesComplimentary
Authorized Signature REQUIRED for	UIRED for CREDIT CARD or IDT		J Name (First/	IDT Approver Name (First/Last) please print		Will you be attending the Friday evening recention at the Marriott?

Department of CME/Conference Management- Unit 1781
The University of Texas MD Anderson Cancer Center
176700/30/117037/41
PO Box 301407
Houston, TX 77230-1407

Non-Profit Org. U.S. Postage P A I D Houston, TX Permit No. 7052